(VTR) Ventas - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US92276F1003
Stock: Senior Housing, Medical Buildings, Research Centers, Healthcare Facilities
Total Rating 49
Risk 35
Buy Signal 0.00
| Risk 5d forecast | |
|---|---|
| Volatility | 19.3% |
| Relative Tail Risk | -6.40% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.19 |
| Alpha | 19.25 |
| Character TTM | |
|---|---|
| Beta | 0.037 |
| Beta Downside | -0.168 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.35% |
| CAGR/Max DD | 1.47 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 159.5556
Description: VTR Ventas March 05, 2026
Ventas Inc. (VTR) is a healthcare real estate investment trust (REIT) with approximately 1,400 properties across North America and the United Kingdom. Healthcare REITs specialize in owning and managing properties in the healthcare sector, often benefiting from stable, long-term leases.
The companys portfolio primarily consists of over 850 senior housing communities. This business model provides housing and services to an aging population, a demographic trend that supports demand for such facilities. Ventas also owns outpatient medical buildings, research centers, and other healthcare facilities.
Ventas leverages operational expertise, data analytics through its Ventas OI platform, and established relationships to drive performance. Understanding the specifics of their portfolio composition and tenant base can be further explored on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 251.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.74 > 1.0 |
| NWC/Revenue: -1.06% < 20% (prev 0.95%; Δ -2.01% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.68b > Net Income 251.4m |
| Net Debt (12.48b) to EBITDA (2.24b): 5.57 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (480.8m) vs 12m ago 12.43% < -2% |
| Gross Margin: -5.90% > 18% (prev 0.43%; Δ -632.6% > 0.5%) |
| Asset Turnover: 21.70% > 50% (prev 18.80%; Δ 2.89% > 0%) |
| Interest Coverage Ratio: 1.14 > 6 (EBITDA TTM 2.24b / Interest Expense TTM 753.8m) |
Altman Z'' -1.74
| A: -0.00 (Total Current Assets 1.33b - Total Current Liabilities 1.39b) / Total Assets 27.59b |
| B: -0.27 (Retained Earnings -7.53b / Total Assets 27.59b) |
| C: 0.03 (EBIT TTM 859.6m / Avg Total Assets 26.89b) |
| D: -1.00 (Book Value of Equity -14.98b / Total Liabilities 15.01b) |
| Altman-Z'' Score: -1.74 = D |
Beneish M -3.54
| DSRI: 0.93 (Receivables 415.6m/375.7m, Revenue 5.83b/4.92b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.08 (AQ_t 0.08 / AQ_t-1 0.93) |
| SGI: 1.18 (Revenue 5.83b / 4.92b) |
| TATA: -0.05 (NI 251.4m - CFO 1.68b) / TA 27.59b) |
| Beneish M-Score: -3.54 (Cap -4..+1) = AAA |
What is the price of VTR shares?
As of March 08, 2026, the stock is trading at USD 84.87 with a total of 1,610,234 shares traded.
Over the past week, the price has changed by -1.50%, over one month by +2.81%, over three months by +5.42% and over the past year by +28.91%.
Over the past week, the price has changed by -1.50%, over one month by +2.81%, over three months by +5.42% and over the past year by +28.91%.
Is VTR a buy, sell or hold?
Ventas has received a consensus analysts rating of 4.45.
Therefore, it is recommended to buy VTR.
- StrongBuy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.2 | 6.2% |
| Analysts Target Price | 90.2 | 6.2% |
VTR Fundamental Data Overview March 02, 2026
P/E Trailing = 159.5556
P/E Forward = 147.0588
P/S = 7.0345
P/B = 3.2667
P/EG = 1.7374
Revenue TTM = 5.83b USD
EBIT TTM = 859.6m USD
EBITDA TTM = 2.24b USD
Long Term Debt = 13.01b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, two quarters ago)
Debt = 13.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.48b USD (from netDebt column, last quarter)
Enterprise Value = 53.40b USD (40.92b + Debt 13.22b - CCE 741.1m)
Interest Coverage Ratio = 1.14 (Ebit TTM 859.6m / Interest Expense TTM 753.8m)
EV/FCF = 40.56x (Enterprise Value 53.40b / FCF TTM 1.32b)
FCF Yield = 2.47% (FCF TTM 1.32b / Enterprise Value 53.40b)
FCF Margin = 22.57% (FCF TTM 1.32b / Revenue TTM 5.83b)
Net Margin = 4.31% (Net Income TTM 251.4m / Revenue TTM 5.83b)
Gross Margin = -5.90% ((Revenue TTM 5.83b - Cost of Revenue TTM 6.18b) / Revenue TTM)
Gross Margin QoQ = -136.0% (prev 41.58%)
Tobins Q-Ratio = 1.94 (Enterprise Value 53.40b / Total Assets 27.59b)
Interest Expense / Debt = 1.17% (Interest Expense 154.5m / Debt 13.22b)
Taxrate = 21.0% (US default 21%)
NOPAT = 679.1m (EBIT 859.6m * (1 - 21.00%))
Current Ratio = 0.96 (Total Current Assets 1.33b / Total Current Liabilities 1.39b)
Debt / Equity = 1.06 (Debt 13.22b / totalStockholderEquity, last quarter 12.53b)
Debt / EBITDA = 5.57 (Net Debt 12.48b / EBITDA 2.24b)
Debt / FCF = 9.48 (Net Debt 12.48b / FCF TTM 1.32b)
Total Stockholder Equity = 11.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.93% (Net Income 251.4m / Total Assets 27.59b)
RoE = 2.10% (Net Income TTM 251.4m / Total Stockholder Equity 11.97b)
RoCE = 3.44% (EBIT 859.6m / Capital Employed (Equity 11.97b + L.T.Debt 13.01b))
RoIC = 2.74% (NOPAT 679.1m / Invested Capital 24.81b)
WACC = 4.80% (E(40.92b)/V(54.14b) * Re(6.05%) + D(13.22b)/V(54.14b) * Rd(1.17%) * (1-Tc(0.21)))
Discount Rate = 6.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 8.69%
[DCF] Terminal Value 88.43% ; FCFF base≈1.21b ; Y1≈1.50b ; Y5≈2.55b
[DCF] Fair Price = 129.9 (EV 74.18b - Net Debt 12.48b = Equity 61.70b / Shares 475.0m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 44.09 | EPS CAGR: 6.54% | SUE: 0.20 | # QB: 0
Revenue Correlation: 98.00 | Revenue CAGR: 12.18% | SUE: 2.54 | # QB: 6
EPS next Quarter (2026-06-30): EPS=0.17 | Chg7d=-0.015 | Chg30d=+0.165 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=0.66 | Chg7d=-0.038 | Chg30d=+0.092 | Revisions Net=+1 | Growth EPS=+45.5% | Growth Revenue=+15.2%
EPS next Year (2027-12-31): EPS=0.97 | Chg7d=-0.083 | Chg30d=+0.007 | Revisions Net=+0 | Growth EPS=+47.2% | Growth Revenue=+12.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 7.3% (Discount Rate 7.9% - Earnings Yield 0.6%)
[Growth] Growth Spread = +8.4% (Analyst 15.7% - Implied 7.3%)
P/E Forward = 147.0588
P/S = 7.0345
P/B = 3.2667
P/EG = 1.7374
Revenue TTM = 5.83b USD
EBIT TTM = 859.6m USD
EBITDA TTM = 2.24b USD
Long Term Debt = 13.01b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, two quarters ago)
Debt = 13.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.48b USD (from netDebt column, last quarter)
Enterprise Value = 53.40b USD (40.92b + Debt 13.22b - CCE 741.1m)
Interest Coverage Ratio = 1.14 (Ebit TTM 859.6m / Interest Expense TTM 753.8m)
EV/FCF = 40.56x (Enterprise Value 53.40b / FCF TTM 1.32b)
FCF Yield = 2.47% (FCF TTM 1.32b / Enterprise Value 53.40b)
FCF Margin = 22.57% (FCF TTM 1.32b / Revenue TTM 5.83b)
Net Margin = 4.31% (Net Income TTM 251.4m / Revenue TTM 5.83b)
Gross Margin = -5.90% ((Revenue TTM 5.83b - Cost of Revenue TTM 6.18b) / Revenue TTM)
Gross Margin QoQ = -136.0% (prev 41.58%)
Tobins Q-Ratio = 1.94 (Enterprise Value 53.40b / Total Assets 27.59b)
Interest Expense / Debt = 1.17% (Interest Expense 154.5m / Debt 13.22b)
Taxrate = 21.0% (US default 21%)
NOPAT = 679.1m (EBIT 859.6m * (1 - 21.00%))
Current Ratio = 0.96 (Total Current Assets 1.33b / Total Current Liabilities 1.39b)
Debt / Equity = 1.06 (Debt 13.22b / totalStockholderEquity, last quarter 12.53b)
Debt / EBITDA = 5.57 (Net Debt 12.48b / EBITDA 2.24b)
Debt / FCF = 9.48 (Net Debt 12.48b / FCF TTM 1.32b)
Total Stockholder Equity = 11.97b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.93% (Net Income 251.4m / Total Assets 27.59b)
RoE = 2.10% (Net Income TTM 251.4m / Total Stockholder Equity 11.97b)
RoCE = 3.44% (EBIT 859.6m / Capital Employed (Equity 11.97b + L.T.Debt 13.01b))
RoIC = 2.74% (NOPAT 679.1m / Invested Capital 24.81b)
WACC = 4.80% (E(40.92b)/V(54.14b) * Re(6.05%) + D(13.22b)/V(54.14b) * Rd(1.17%) * (1-Tc(0.21)))
Discount Rate = 6.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 8.69%
[DCF] Terminal Value 88.43% ; FCFF base≈1.21b ; Y1≈1.50b ; Y5≈2.55b
[DCF] Fair Price = 129.9 (EV 74.18b - Net Debt 12.48b = Equity 61.70b / Shares 475.0m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 44.09 | EPS CAGR: 6.54% | SUE: 0.20 | # QB: 0
Revenue Correlation: 98.00 | Revenue CAGR: 12.18% | SUE: 2.54 | # QB: 6
EPS next Quarter (2026-06-30): EPS=0.17 | Chg7d=-0.015 | Chg30d=+0.165 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=0.66 | Chg7d=-0.038 | Chg30d=+0.092 | Revisions Net=+1 | Growth EPS=+45.5% | Growth Revenue=+15.2%
EPS next Year (2027-12-31): EPS=0.97 | Chg7d=-0.083 | Chg30d=+0.007 | Revisions Net=+0 | Growth EPS=+47.2% | Growth Revenue=+12.3%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 7.3% (Discount Rate 7.9% - Earnings Yield 0.6%)
[Growth] Growth Spread = +8.4% (Analyst 15.7% - Implied 7.3%)